CStone Pharmaceuticals (CStone Pharma-B, 02616 HK) announced that preclinical data for three proprietary antibody-drug conjugates (ADCs)—CS5007, CS5008 and CS5006—have been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held in San Diego from 17–22 April 2026. Abstracts will be published in Cancer Research on 3 April 2026.

CS5007 targets EGFR and HER3 and is positioned as a potential best-in-class therapy for heterogeneous solid tumours such as non-small cell lung cancer, colorectal cancer, squamous cell carcinoma of the head and neck and triple-negative breast cancer. The poster (Board #11) is scheduled for 20 April 2026, 9:00 AM–12:00 PM PT.

CS5008 combines SSTR2 and DLL3 targeting for small cell lung cancer, neuroendocrine neoplasms and other malignancies characterised by dual antigen expression. Its poster (Board #10) will be presented at the same session on 20 April 2026.

CS5006, an integrin β4-targeting ADC, is described as a potential first-in-class candidate with limited normal-tissue expression and broad tumour coverage across NSCLC, CRC and SCCHN. The poster (Board #9) will also be displayed on 20 April 2026.

Corporate snapshot: founded in late 2015, CStone has launched four innovative drugs, obtained 20 new-drug approvals across nine indications and is advancing 16 pipeline assets—including ADCs, multispecific antibodies and precision medicines—through its fully integrated R&D and commercial platform.

Regulatory note: the company highlights that successful development and commercialisation of CS5006, CS5007 and CS5008 are not guaranteed, and shareholders should exercise caution when dealing in the company’s securities.